If the novel factor XI inhibitor abelacimab reaches the market for patients with atrial fibrillation (AF) who require anticoagulation, it may not be necessary to interrupt treatment ahead of invasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results